NystatinLF liposomal form of nystatin data

The Woodlands, Texas, company reported results of a Phase I dose tolerance study, which showed success in treating more than one-third of the 32 patients enrolled, who had failed other anti-fungal therapies.

One of four dose levels between 2 and 8 mg/kg was tested in each neutropenic cancer patient, without a maximum tolerated dose being reached. No dose-limiting side effects were apparent. Infusion-related adverse events included fever, chills, nausea and skin rash. ...